Feb 22 2022

Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually

By |2022-02-21T18:59:51-05:00February 22nd, 2022|Featured, Investor News, Medical, News, Press Releases|1 Comment

Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases.  With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens.  See Table Below.  This could lead to ...

Feb 8 2022

Halberd Eliminates 100% of Tau Protein From CSF – The 9th of 10 Target Neurodegenerative Disease Antigens

By |2022-02-07T18:58:11-05:00February 8th, 2022|Featured, Investor News, News|0 Comments

Tau buildup in the brain is linked to Alzheimer’s and other neurodegenerative diseases. Jackson Center, PA, February 8, 2022 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid (CSF) in less than 20 minutes with its patented extracorporeal laser exposure process.  Excess Tau in CSF ...

Jan 5 2022

Halberd Corporation Now an Official US Government Contractor

By |2022-01-04T20:14:00-05:00January 5th, 2022|Investor News, News, Press Releases|0 Comments

Halberd to bid on Additional Federal Contracts with the Federal Government Jackson Center, PA, January 5, 2022 – Halberd Corporation (OTC PINK:HALB) is now registered with the Federal Government’s System for Award Management allowing Halberd to bid on Federal contracts and conduct business with the Federal government in the areas of Research and Development in ...

Go to Top